The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, has reiterated its bullish view on ImmuPharma.
ImmuPharma (IMM) a pharmaceutical development company that develops novel medicines, in specialist markets with serious unmet needs, is currently focused on developing its lead asset addressing Lupus: Lupuzor.
The Life Sciences Division, in a note to investors, commented on AstraZeneca’s Anifrolumab and its navigation through a Phase III lupus clinical trial, alluding to the potential of AIM listed ImmuPharma’s LupuzorTM.
Dr. Navid Malik, Head of Life Sciences Research at TLSD, said in a research note: "Lupus still represents a major area of unmet medical need and there is a strong need for safe and efficacious products.”
Dr. Navid adds: “We believe that the recent update for Anifrolumab is positive for the Lupus field, but also reminds us that LupuzorTM could represent a highly successful product if it successfully navigates a second Phase III clinical trial.”
“Now that we understand the target patient group of Lupus patients who respond best to the drug, we see the path to market as being de-risked."
Shares in ImmuPharma fell dramatically after its Phase III Trial last April failed to meet its primary endpoint, but confirmed the safety profile of Lupuzor™, with zero serious adverse events reported.
The fact that Lupuzor is a late stage asset, with a “unique mechanism of action", The Life Sciences Division view it as an important potential treatment for Lupus patients.
Pharmaceutical investors will be closely following the data published from AstraZeneca’s TULIP II study and its implications..
Follow News & Updates from ImmuPharma here: